Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.

[1]  Tammy O. Tengs,et al.  A Meta-Analysis of Quality-of-Life Estimates for Stroke , 2012, PharmacoEconomics.

[2]  Deepak L. Bhatt,et al.  Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  L. Goldman,et al.  Cost-Effectiveness of Clopidogrel: Seeing through the Smoke , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[4]  S. Mehta,et al.  Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. , 2007, The Canadian journal of cardiology.

[5]  Deepak L. Bhatt,et al.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.

[6]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[7]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[8]  S. Yusuf,et al.  Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. , 2006, American heart journal.

[9]  R. Collins,et al.  Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[10]  B. Lewis,et al.  Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. , 2005, JAMA.

[11]  Roland Chen,et al.  Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. , 2005, Journal of the American College of Cardiology.

[12]  Deepak L. Bhatt,et al.  A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. , 2005, American heart journal.

[13]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[14]  S. Yusuf,et al.  Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. , 2005, Journal of the American College of Cardiology.

[15]  J. Caro,et al.  Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure , 2005, Circulation.

[16]  P. Heidenreich,et al.  A Cost-Effectiveness Analysis of Combination Antiplatelet Therapy for High-Risk Acute Coronary Syndromes: Clopidogrel plus Aspirin versus Aspirin Alone , 2005, Annals of Internal Medicine.

[17]  S. Yusuf,et al.  The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[18]  J. Caro,et al.  Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  Deepak L. Bhatt,et al.  Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. , 2004, American heart journal.

[20]  D. Owens,et al.  Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis ☆ , 2004 .

[21]  J. Caro,et al.  Cost of managing an episode of relapse in multiple sclerosis in the United States , 2003, BMC health services research.

[22]  J. Caro,et al.  Cost of managing complications resulting from type 2 diabetes mellitus in Canada , 2003, BMC health services research.

[23]  J. D. de Lemos,et al.  Aspirin, clopidogrel, or both for secondary prevention of coronary disease. , 2003, The New England journal of medicine.

[24]  S. Ramsey.  Aspirin, clopidogrel, or both for secondary prevention of coronary disease. , 2003, The New England journal of medicine.

[25]  B J O'Brien,et al.  Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods , 2002, Statistical methods in medical research.

[26]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[27]  C. Cannon,et al.  Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. , 2002, JAMA.

[28]  Karen M Kuntz,et al.  Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. , 2002, The New England journal of medicine.

[29]  P. Beck,et al.  Health Databases in Saskatchewan , 2002 .

[30]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[31]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[32]  D. Getsios,et al.  Diabetes in Canada: direct medical costs of major macrovascular complications. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[33]  M A Koopmanschap,et al.  The friction cost method for measuring indirect costs of disease. , 1995, Journal of health economics.

[34]  R. Klein,et al.  The Beaver Dam Health Outcomes study , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[35]  L Goldman,et al.  Stability of Time-tradeoff Utilities in Survivors of Myocardial Infarction , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[36]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[37]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[38]  B. Culliton,et al.  Post-marketing surveillance. , 1980, British medical journal.